55 results
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
shall pay all fees and expenses incident to the performance of or compliance with ARTICLE 5 of this Agreement by the Company, including without … of the shares of common stock. We will bear all fees and expenses incident to our obligation to register the shares of common stock.
Each selling
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
the Company, the Subsidiaries or any of their properties or assets to notify in writing, any person of any Personal Data or security-related incident … , the Company hereby agrees to pay all costs and expenses incident to the performance of its obligations hereunder, including the following: (i) all
8-K
EX-1.2
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
to be performed or satisfied hereunder at or prior to such Closing Date.
(d) All corporate proceedings and other legal matters incident
424B5
elvz5l2602n a5
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
eehycaf0b82uhd3 1uj
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-10.1
ttggzei3loxx
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-1.1
rz7p rg7c
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
faukyog ptgp
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
3r39z4cxfw
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-1.1
23vw00v vqcvgf
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
8-K
EX-1.1
6g6wnar4
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
424B5
sawwhbz9ab o5vved4
25 Jun 20
Prospectus supplement for primary offering
4:01pm